Physician profile
Nicole Johnston
NPI 1851489223
$1,735.61
in general payments reported to CMS, 2019-2025
27 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $81.71 · 2021: $290 · 2022: $341 · 2023: $111 · 2024: $173 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.59 | 2019-2024 | |
| Astellas Pharma US INC | $214.10 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $209.14 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $151.50 | 2021-2022 | |
| Therapeuticsmd, INC. | $107.99 | 2019-2022 | |
| Millicent US INC | $80.66 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Exeltis, USA INC. | $70.12 | 2022-2025 | Slynd |
| Pfizer INC. | $45.60 | 2019-2025 | |
| Coopersurgical, INC. | $43.52 | 2020-2024 | Summit Doppler |
| Organon LLC | $42.60 | 2022-2025 | Nexplanon |
| Amgen INC. | $39.91 | 2019-2023 | Evenity, Prolia |
| Dexcom, INC. | $36.64 | 2023 | Dexcom G6 Transmitter |
| Duchesnay USA Incorporated | $30.83 | 2019 | |
| Allergan, INC. | $24.85 | 2019 | |
| Baxter Healthcare | $24.81 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $24.12 | 2025 | Prevena |
| Scynexis, INC. | $22.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.54 | 2019-2020 | |
| Shield Therapeutics INC | $20.52 | 2025 | |
| Sage Therapeutics, LLC | $19.38 | 2024 | |
| Urovant Sciences INC | $17.33 | 2022 | |
| Shire North American Group INC | $16.65 | 2019 | |
| Novo Nordisk INC | $16.07 | 2021 | |
| Lilly USA, LLC | $15.09 | 2024 | Zepbound |
| Agile Therapeutics, INC. | $13.44 | 2021 | |
| Sumitomo Pharma America, INC. | $13.41 | 2023 | Myfembree |
| Myovant Sciences INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.